Prevention & Treatment

Table of Contents

  1. Health Behaviour Management
  2. Indications for Drug Therapy for Adults With Hypertension Without Compelling Indications for Specific Agents
  3. Choice of therapy for Adults With Hypertension Without Compelling Indications for Specific Agents
  4. Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents
  5. Goals of Therapy for Adults With Hypertension Without Compelling Indications for Specific Agents
  6. Treatment of Hypertension in Association With Ischemic Heart Disease
  7. Treatment of Hypertension in Association With Heart Failure
  8. Treatment of Hypertension in Association With Stroke
  9. Treatment of Hypertension in Association With Left Ventricular Hypertrophy
  10. Treatment of Hypertension in Association With Nondiabetic Chronic Kidney Disease
  11. Treatment of Hypertension in Association With Renovascular Disease
  12. Treatment of Hypertension in Association With Diabetes Mellitus
  13. Adherence Strategies for Patients
  14. Treatment of Secondary Hypertension Due to Endocrine Causes
  15. Supplementary Tables

Credits

Subgroup Members:

Section I. Health Behaviour Management: Simon L. Bacon, PhD; Janusz Kaczorowski, PhD; Luc Trudeau, MD; Swapnil Hiremath, MD MPH; Norman RC. Campbell, MD; Michael Roerecke, PhD; Joanne Arcand, PhD RD

Section II. Indications for Drug Therapy for Adults with Hypertension Without Compelling indications for Specific Agents: George K. Dresser, MD PhD; Robert J. Herman, MD; Pavel Hamet, MD PhD; Ellen Burgess, MD; Richard Lewanczuk, MD PhD; Jean C. Grégoire, MD; Steven E. Gryn, MD; Luc Poirier, BPharm MSc

Section III. Choice of Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents: George K. Dresser, MD PhD; Robert J. Herman, MD; Pavel Hamet, MD PhD; Ellen Burgess, MD; Richard Lewanczuk, MD PhD; Jean C. Grégoire, MD; Steven E. Gryn, MD; Luc Poirier, BPharm MSc

Section IV. Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents: Ross D. Feldman, MD; Ernesto L. Schiffrin, MD PhD; Robert A. Hegele, MD; Philip A. McFarlane, MD PhD; Andrew Pipe, CM MD; Paul Oh, MD; Peter Selby, MBBS MHSc; Milan Gupta, MD

Section V. Goal of Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents: George K. Dresser, MD PhD; Robert J. Herman, MD; Pavel Hamet, MD PhD; Ellen Burgess, MD; Richard Lewanczuk, MD PhD; Jean C. Grégoire, MD; Steven E. Gryn, MD; Luc Poirier, BPharm MSc

Section VI. Treatment of Hypertension in Association with Ischemic Heart Disease: Simon W. Rabkin, MD, Gordon W. Moe, MD MSc, Jonathan G. Howlett, MD

Section VII. Treatment of Hypertension in Association with Heart Failure: Simon W. Rabkin, MD, Gordon W. Moe, MD MSc, Jonathan G. Howlett, MD

Section VIII. Treatment of Hypertension in Association with Stroke: Patrice Lindsay, RN PhD., Mike Sharma, MD MSc., Michael D. Hill, MD MSc,, Thalia Field, MD MHSc., Theodore H. Wein, MD., Ashkan Shoamanesh, MD

Section IX. Treatment of Hypertension in Association with Left Ventricular Hypertrophy: Simon W. Rabkin, MD, Gordon W. Moe, MD MSc, Jonathan G. Howlett, MD

Section X. Treatment of Hypertension in Association with Non-Diabetic Chronic Kidney Disease: Marcel Ruzicka, MD PhD; Sheldon W. Tobe, MD MScCH; Ramesh Prasad, MBBS MSc MA PhD; Michel Vallée, MD PhD; Cedric Edwards, MD

Section XI. Treatment of Hypertension in Association with Renovascular Disease: Marcel Ruzicka, MD PhD; Sheldon W. Tobe, MD MScCH; Ramesh Prasad, MBBS MSc MA PhD; Michel Vallée, MD PhD; Cedric Edwards, MD

Section XII. Treatment of Hypertension in Association with Diabetes Mellitus: Richard E. Gilbert, MBBS PhD; Lawrence A. Leiter, MD; Charlotte Jones, PhD MD; Sheldon W. Tobe, MD MScCH; Vincent Woo, MD

Section XIII: Adherence Strategies for Patients: Tavis S. Campbell, PhD RPsych; Ross D. Feldman, MD; Alain Milot, MD MSc; Kim L. Lavoie, PhD; Ross T. Tsuyuki, BSc(Pharm) PharmD MSc

Section XIV. Treatment of Secondary Hypertension due to Endocrine Causes: Ally P.H. Prebtani, MD; Gregory Kline, MD, Ernesto L. Schiffrin, MD PhD; Andrew Don-Wauchope, MD

Central Review Committee:

Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia, BSc MD MSc; Meranda Nakhla, MD MSc

Co-Chairs:

Doreen M. Rabi, MD MSc, Stella S. Daskalopoulou, MD MSc DIC PhD